SCHEMBL1359635

SCHEMBL1359635

CC(=O)N1CCN(C(=O)c2coc3c(C(C)(C)C)cc(-c4ccc[nH]c4=O)cc23)CC1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.38
HSP90AB1 P08238 1/20 0.38
PARP1 P09874 4/20 0.35
LTA4H P09960 1/20 0.34
CYP3A4 P08684 5/20 0.33
CYP1A2 P05177 3/20 0.33
CYP2C19 P33261 3/20 0.33
CYP2C9 P11712 2/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
KMT2A Q03164 1/20 0.33
MAP3K11 Q16584 2/20 0.32
RBP4 P02753 1/20 0.32
RAB9A P51151 1/20 0.31
CRBN Q96SW2 2/20 0.31
ITK Q08881 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1359385 0.93 MAPT (0.36) CYP3A4MEN1ALDH1A1LMNAMAPT
SCHEMBL1359911 0.93 MAPT (0.34) PARP1CYP3A4CYP1A2CYP2C19CYP2C9
SCHEMBL1359529 0.92 MAPT (0.37) CYP3A4MEN1ALDH1A1LMNAMAPT
SCHEMBL1358783 0.91 HSP90AA1 (0.39) HSP90AA1HSP90AB1ALDH1A1
SCHEMBL1357846 0.90 HSP90AA1 (0.40) HSP90AA1HSP90AB1CYP3A4CYP1A2CYP2C19
SCHEMBL1360394 0.89 PARP1 (0.41) PARP1HPGDKMT2A
SCHEMBL1358003 0.89 CRBN (0.36) CYP3A4CYP1A2CYP2C19CYP2C9CRBN
SCHEMBL1360205 0.88 KDM1A (0.38) HSP90AA1HSP90AB1CYP3A4
SCHEMBL1360132 0.87 CYP3A4 (0.35) HSP90AA1HSP90AB1CYP3A4
SCHEMBL1358320 0.87 ALDH1A1 (0.39) PARP1CYP3A4ALDH1A1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067442-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2011-11-29 US claimed
US-20100081658-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-04-01 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081658-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS EIF2AK2, POLR2A, HCCS HSP90AA1 2114/4885HSP90AB1 1378/4885PARP1 482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.